Pfizer, BioNTech Announce Top-line Results In Phase 3 Trial Of MRNA-based Combination Vaccine

RTTNews | 131 hari yang lalu
Stocktwits
Pfizer, BioNTech Announce Top-line Results In Phase 3 Trial Of MRNA-based Combination Vaccine

(RTTNews) - Drug giant Pfizer Inc. (PFE) and BioNTech SE (BNTX) announced Friday top-line results from their Phase 3 clinical trial to evaluate the companies' combined mRNA vaccine candidate against influenza and COVID-19 in healthy individuals 18-64 years of age.

The combination candidate consists of Pfizer's mRNA-based influenza vaccine candidate with the companies' licensed COVID-19 vaccine.

The Phase 3 trial measured two primary immunogenicity objectives (immunogenicity against SARS-CoV-2 as well as immunogenicity against influenza A and B), of which one was met.

In a separate Phase 2 trial, Pfizer evaluated trivalent influenza mRNA standalone vaccine candidates which demonstrated robust immunogenicity in individuals 18-64 years of age.

The companies are evaluating adjustments to the combination vaccine candidate aimed at improving immune responses against influenza B and will discuss next steps with health authorities.

Teg: PFE BNTX
Stocktwits
read more
Pfizer Launches Digital Platform PfizerForAll

Pfizer Launches Digital Platform PfizerForAll

Drug giant Pfizer Inc. (PFE) announced Tuesday the introduction of PfizerForAll, a user-friendly digital platform designed to make access to healthcare and managing health and wellness more seamless for people across the U.S.
RTTNews | 120 hari yang lalu
FDA Approves Updated Pfizer, Moderna Covid Vaccines Against Current Variants

FDA Approves Updated Pfizer, Moderna Covid Vaccines Against Current Variants

The U.S. Food and Drug Administration approved and granted emergency use authorization or EUA for updated Covid vaccines from Pfizer Inc. and ModernaTX Inc. for use against currently circulating variants. The approval for the updated mRNA COVID-19 vaccines (2024-2025 formula) comes as the Covid cases are surging in the United States.
RTTNews | 125 hari yang lalu
Pfizer Boost FY24 Outlook - Update

Pfizer Boost FY24 Outlook - Update

While reporting financial results for the second quarter, drug major Pfizer Inc. (PFE) raised its adjusted earnings and revenue guidance for the full-year 2024.
RTTNews | 148 hari yang lalu
Pfizer's Hospira Recalls Select Hydrochloride Injection Carpuject Units

Pfizer's Hospira Recalls Select Hydrochloride Injection Carpuject Units

Hospira, Inc., affiliated to dug major Pfizer Inc., is recalling select lots of Buprenorphine Hydrochloride Injection Carpuject Units and Labetalol Hydrochloride Injection Carpuject Units, according to the U.S. Food and Drug Administration. The recall was initiated due to the potential for incomplete crimp seals. The company has received one customer complaint for one leaking unit.
RTTNews | 216 hari yang lalu
Amazon, Microsoft, Pfizer To Invest Billions In French Projects

Amazon, Microsoft, Pfizer To Invest Billions In French Projects

Major companies, including Amazon.com Inc., Microsoft Corp., Morgan Stanley, Pfizer and others, have announced around 15 billion euros or $16.2 billion worth foreign investments in France as part of the country's annual 'Choose France' business summit, reports said. French President Emmanuel Macron kicks off the summit of 180 CEOs and executives on Monday, aiming to showcase foreign investment.
RTTNews | 226 hari yang lalu
BioNTech Slips To Loss In Q1

BioNTech Slips To Loss In Q1

Immunotherapy company Biopharmaceutical New Technologies or BioNTech SE (BNTX) reported Monday a net loss of 315.1 million euros or 1.31 euros per share for the first quarter, compared to net profit of 502.2 million euros or 2.05 euros per share in the prior-year quarter.
RTTNews | 233 hari yang lalu
Alat
Kalendar Ekonomi
Market Hours
Interest Rates
Holidays Calendar
Pasaran Forex
Volatiliti Forex
Korelasi Forex
Berita Forex
forex analysis
Data COT
Kecairan
Kalkulator Forex
Peta Panas Forex
Indicators Heatmap
Komuniti
Komuniti
Sistem
Sistem Paling Popular
Strategi
Peraduan
Carta Forex
Sentimen Forex
Petunjuk Outlook
Ulasan
Broker
Prop Trading Firms
Perkhidmatan VPS
Penyedia Isyarat
Perkhidmatan Pengaturcaraan EA
Affiliate Programs
Perkhidmatan PAMM Broker
Perkhidmatan Program Rebat
Platform Dagangan
Penasihat Pakar
Pertukaran Kripto
Trading Courses
Broker
Spread Forex
Sebut Harga Forex Broker
Pertukaran Broker Forex
Jumlah Broker Forex
Promosi Broker Forex Broker News
Platform
Widget
Ciri-ciri
API
RSS
Stock Portfolio
Affiliate Software
Carta Lanjutan
Sokongan
Soalan Lazim
Bantuan
Hubungi Kami
Laporkan pepijat!
Mengenai
Blog
&salin; 2024 Myfxbook Ltd. Hak Cipta Terpelihara.
PERINGATAN RISIKO TINGGI: Perdagangan pertukaran mata wang asing mempunyai risiko tinggi yang mungkin tidak sesuai untuk semua jenis pelabur. Leveraj menimbulkan risiko dan kerugian tambahan. Sebelum anda memutuskan untuk berdagang pertukaran mata wang asing, pertimbangkan dengan teliti objektif pelaburan, tahap pengalaman dan toleransi risiko anda. Anda berkemungkinan kehilangan sebahagian atau semua pelaburan awal anda. Jangan melaburkan wang yang anda tidak mampu untuk kehilangan. Didik diri anda tentang risiko yang berkaitan dengan perdagangan pertukaran asing, dan dapatkan nasihat daripada penasihat bebas kewangan atau cukai jika anda mempunyai sebarang pertanyaan mengenainya. Semua data dan maklumat yang disediakan adalah semata-mata untuk tujuan maklumat, dan bukan bertujuan untuk tujuan perdagangan atau nasihat. Prestasi masa lalu tidak semestinya menunjukkan hasil masa depan.